ストックスクリーナーアプリを入手
3.76
4.93%
-0.195
前日終値:
$3.955
開ける：
$4
24時間の取引高:
2.99M
Relative Volume:
0.70
時価総額：
$818.56M
収益：
$35.54M
当期純損益:
$-59.14M
株価収益率:
-10.34
EPS:
-0.3637
ネットキャッシュフロー:
$-80.19M
1週間 パフォーマンス:
-1.57%
1か月 パフォーマンス:
+29.21%
6か月 パフォーマンス:
-13.56%
1年 パフォーマンス:
+44.62%
1日の値動き範囲:
$3.62
$4.02
1週間の範囲:
$3.62
$4.02
52週間の値動き範囲:
$1.72
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
名前
Cytomx Therapeutics Inc
セクター
電話
650.515.3185
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
3.76 | 818.56M | 35.54M | -59.14M | -80.19M | -0.3637 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | アップグレード | JP Morgan | Neutral → Overweight |
| 2026-01-20 | 開始されました | Guggenheim | Buy |
| 2025-09-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-09-17 | 再開されました | Barclays | Overweight |
| 2025-07-31 | 開始されました | Oppenheimer | Outperform |
| 2025-05-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 再開されました | Piper Sandler | Overweight |
| 2024-05-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | アップグレード | Wedbush | Neutral → Outperform |
| 2024-05-06 | アップグレード | Jefferies | Hold → Buy |
| 2024-04-22 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-11-14 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-07-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2022-01-18 | アップグレード | Barclays | Underweight → Overweight |
| 2021-11-15 | 開始されました | BTIG Research | Buy |
| 2021-05-28 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 開始されました | JP Morgan | Overweight |
| 2021-03-23 | アップグレード | Jefferies | Hold → Buy |
| 2020-09-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-06-01 | ダウングレード | Jefferies | Buy → Hold |
| 2020-05-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-24 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-03-04 | 開始されました | Barclays | Equal Weight |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
| 2019-11-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-05-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 開始されました | Barclays | Overweight |
| 2018-11-26 | 開始されました | Piper Jaffray | Overweight |
| 2018-10-15 | 開始されました | Goldman | Neutral |
| 2018-09-13 | 開始されました | H.C. Wainwright | Buy |
| 2018-06-01 | 開始されました | SunTrust | Buy |
| 2018-01-05 | 開始されました | Citigroup | Buy |
| 2017-09-08 | 開始されました | Wedbush | Outperform |
| 2017-03-27 | 開始されました | H.C. Wainwright | Buy |
| 2017-03-02 | 開始されました | Instinet | Buy |
| 2017-01-03 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Cytomx Therapeutics Inc (CTMX) 最新ニュース
CytomX Therapeutics (CTMX) Holds Near Support After Slight DipUpthrust Pattern - dars.gov.et
CytomX Therapeutics updates investors on its pipeline progress amid Nasdaq listing - ad-hoc-news.de
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why - Yahoo Finance
CytomX Therapeutics focuses on its antibody-drug conjugate platform - ad-hoc-news.de
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - Yahoo Finance
CytomX Therapeutics outlines its oncology focus as investors watch Nasdaq trading - ad-hoc-news.de
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits
CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Value Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to Russell Microcap Value Benchmark Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Growth Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell Microcap Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Growth Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000 Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Value Benchmark - marketscreener.com
Price to book forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Price to earnings forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Enterprise value to EBIT forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Price to sales forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Enterprise value to revenue forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
CytomX Therapeutics, Inc. Actuals & Estimates (NASDAQ:CTMX) - TradingView
CTMX Forecast — Price Target — Prediction for 2027 - TradingView
CytomX Shareholders Approve Expanded Equity and Capital Plans - The Globe and Mail
Form 4 CytomX Therapeutics Inc For: 22 June By Investing.com - Investing.com India
CytomX Therapeutics Amends Equity Incentive and Employee Stock Purchase Plans Following 2026 Shareholder Approval – Minichart - Minichart
CytomX Therapeutics stockholders approve share increases and board elections - Investing.com
CytomX Therapeutics stockholders approve share increases and board elections By Investing.com - Investing.com Canada
Form 8K CytomX Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
CytomX (CTMX) director Su Zhen awarded 59,000 stock options at $2.96 - Stock Titan
[8-K] CytomX Therapeutics, Inc. Reports Material Event - Stock Titan
Director at CytomX (NASDAQ: CTMX) awarded 59,000 stock options - Stock Titan
Director at CytomX (NASDAQ: CTMX) receives 59,000-stock option award - Stock Titan
CytomX (CTMX) director receives 59,000 stock options at $2.96 - Stock Titan
CytomX (CTMX) director Halley Gilbert receives 59,000 stock options at $2.96 strike - Stock Titan
CytomX (CTMX) director Alan Ashworth receives grant of 59,000 stock options - Stock Titan
CytomX (CTMX) director Elaine Jones awarded 59,000 stock options at $2.96 strike - Stock Titan
Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now? - Insider Monkey
CytomX Therapeutics Inc (CTMX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CytomX CFO Ogden sells $4,953 in company stock By Investing.com - Investing.com South Africa
CytomX CFO Ogden sells $4,953 in company stock - Investing.com
CytomX Therapeutics (CTMX) CFO sells shares to cover RSU tax withholding - Stock Titan
10 Best Growth Stocks Under $30 to Buy Now - Insider Monkey
CytomX Therapeutics Inc (CTMX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CytomX Therapeutics Inc (CTMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CytomX Therapeutics Inc (CTMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CytomX Therapeutics Inc (CTMX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CytomX Therapeutics Inc (CTMX) Valuation: PE, PB & Fair Value Analysis - TradingKey
CytomX Therapeutics Inc (CTMX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cytomx Therapeutics Inc (CTMX) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):